Skip to content

Trial Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of RO7247669 (PD1-LAG3) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).



ACTRN/NCT /ethics:


Scientific title:

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Sponsor / Cooperative group:

Hoffmann-La Roche

Trial & Patient Characteristics

Cancer TypeRenal Cell Carcinoma
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
Tumour Stream -
Cancer Stage-
Anticipated Start Date2023-04-21
Anticipated End Date2026-03-31

Participating Hospitals

HospitalIcon Cancer Centre - Tennyson and Windsor Garden
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2204
Principal InvestigatorAnnabel Smith
Recruitment StatusRecruiting